Breast Cancer Screening Adherence for Women at Moderate Risk for Breast Cancer
Launched by UNIVERSITY OF SOUTHERN CALIFORNIA · Jul 17, 2025
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how well women who have a moderate risk of developing breast cancer stick to recommended breast cancer screening tests, like mammograms and MRIs. The goal is to understand what helps or makes it harder for these women to follow through with regular screenings. This information could help improve future screening programs and support for women at risk.
Women between 30 and 75 years old may be eligible if they have a moderate risk of breast cancer either because of certain gene changes known to increase risk or because of a calculated estimate of their lifetime breast cancer risk (between 20% and 40%). Participants must have had a breast cancer risk assessment at USC Norris or LA General Hospital at least a year ago and were advised to have yearly breast screening. Women who have had breast cancer before, metastatic cancer, or preventive breast removal surgery before their risk assessment cannot join. Those who participate can expect to share information about their screening habits and experiences, which will help researchers learn what encourages or discourages regular breast cancer screening.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • \* \>= 30 years
- • =\< 75 years
- * Women with either:
- • Genetic test results showing moderately increased breast cancer risk due to a pathogenic/likely pathogenic variant in ATM, CHEK2, BARD1, RAD51C, or RAD51D (Mutation carrier group) OR
- • Calculated lifetime breast cancer risk estimates between 20% and 40% according to the Tyrer-Cuzick V8.0B empiric risk model (Empiric risk group)
- • Patients provided breast cancer risk assessments by genetic counselors at USC Norris or LA General Hospital beginning in 2021 and at least 12 months ago
- • Women recommended to undergo annual breast MRI and/or annual mammogram beginning at the time of their genetic counseling risk assessment
- • English or Spanish speaking patients
- Exclusion Criteria:
- • \* History of breast cancer before genetic counseling at University of Southern California (USC)
- • Any metastatic cancer diagnosis at time of genetic counseling risk assessment
- • Deceased
- • Patient underwent a risk reducing mastectomy before their genetic counseling risk assessment
About University Of Southern California
The University of Southern California (USC) is a prestigious research institution located in Los Angeles, California, known for its commitment to advancing knowledge and innovation in various fields, including medicine and health sciences. As a clinical trial sponsor, USC leverages its extensive resources, interdisciplinary expertise, and state-of-the-art facilities to conduct cutting-edge research aimed at improving patient outcomes and public health. The university fosters collaboration among its diverse faculty and students, ensuring a dynamic environment for the development and implementation of clinical studies that adhere to the highest ethical and scientific standards. Through its clinical trials, USC aims to contribute to the advancement of medical science and the translation of research findings into practical applications that benefit communities locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Los Angeles, California, United States
Los Angeles, California, United States
Patients applied
Trial Officials
Jacob Comeaux
Principal Investigator
University of Southern California
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported